Urotensin-II

Urotensin-II is a peptide that was first discovered in the teleost fish and is known to be the most potent vasoconstrictor identified to date. It is a cyclic peptide and is composed of 11 amino acids. Urotensin-II is expressed in various tissues, including the kidney, heart, and blood vessels, and has been implicated in a number of physiological and pathological processes.

Structure[edit | edit source]

Urotensin-II is a cyclic peptide, meaning its amino acids are arranged in a ring structure. It is composed of 11 amino acids, with a sequence of Cys-Phe-Trp-Lys-Tyr-Cys-Val. The two cysteine residues form a disulfide bridge, which is crucial for the peptide's biological activity.

Function[edit | edit source]

Urotensin-II is a potent vasoconstrictor, meaning it causes the narrowing of blood vessels, which increases blood pressure. It is more potent than endothelin-1, another potent vasoconstrictor. Urotensin-II also has other functions, such as promoting the growth of smooth muscle cells and inducing the release of pro-inflammatory cytokines.

Role in Disease[edit | edit source]

Urotensin-II has been implicated in a number of diseases, including cardiovascular disease, renal disease, and diabetes. Elevated levels of Urotensin-II have been found in patients with these diseases, suggesting a potential role in their pathogenesis. In addition, Urotensin-II has been shown to promote the growth of cancer cells, suggesting a potential role in oncogenesis.

Therapeutic Potential[edit | edit source]

Given its role in various diseases, Urotensin-II is being investigated as a potential therapeutic target. Several Urotensin-II receptor antagonists have been developed and are currently being tested in preclinical and clinical trials.